Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a 5-year survival rate of 6% following a diagnosis, and novel therapeutic modalities are needed. Protease-activated receptor 1 (PAR1) is abundantly overexpressed by both tumor cells and multiple stroma cell subsets...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Hao-Chien, Fan, Ming-Huei, Wang, Daniel, Miao, Carol H., Su, Pong, Liu, Chao-Lien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478223/
https://www.ncbi.nlm.nih.gov/pubmed/37667257
http://dx.doi.org/10.1186/s12916-023-03053-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478223/
https://www.ncbi.nlm.nih.gov/pubmed/37667257
http://dx.doi.org/10.1186/s12916-023-03053-9

Ejemplares similares